AGL 38.55 Decreased By ▼ -0.01 (-0.03%)
AIRLINK 200.83 Decreased By ▼ -6.94 (-3.34%)
BOP 10.19 Increased By ▲ 0.13 (1.29%)
CNERGY 6.57 Decreased By ▼ -0.51 (-7.2%)
DCL 9.68 Decreased By ▼ -0.31 (-3.1%)
DFML 39.90 Decreased By ▼ -1.24 (-3.01%)
DGKC 97.67 Decreased By ▼ -5.79 (-5.6%)
FCCL 35.10 Decreased By ▼ -1.25 (-3.44%)
FFBL 86.00 Decreased By ▼ -5.59 (-6.1%)
FFL 13.95 Decreased By ▼ -0.65 (-4.45%)
HUBC 130.45 Decreased By ▼ -8.98 (-6.44%)
HUMNL 14.00 Decreased By ▼ -0.10 (-0.71%)
KEL 5.64 Decreased By ▼ -0.33 (-5.53%)
KOSM 7.30 Decreased By ▼ -0.56 (-7.12%)
MLCF 45.60 Decreased By ▼ -1.68 (-3.55%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 221.50 Decreased By ▼ -1.16 (-0.52%)
PAEL 38.45 Increased By ▲ 0.34 (0.89%)
PIBTL 8.96 Decreased By ▼ -0.31 (-3.34%)
PPL 196.85 Decreased By ▼ -9.00 (-4.37%)
PRL 38.85 Decreased By ▼ -1.00 (-2.51%)
PTC 25.60 Decreased By ▼ -1.02 (-3.83%)
SEARL 104.50 Decreased By ▼ -5.74 (-5.21%)
TELE 9.06 Decreased By ▼ -0.17 (-1.84%)
TOMCL 36.41 Decreased By ▼ -1.80 (-4.71%)
TPLP 13.64 Decreased By ▼ -0.13 (-0.94%)
TREET 25.20 Decreased By ▼ -1.25 (-4.73%)
TRG 58.10 Decreased By ▼ -2.44 (-4.03%)
UNITY 33.55 Decreased By ▼ -0.59 (-1.73%)
WTL 1.73 Decreased By ▼ -0.15 (-7.98%)
BR100 11,896 Decreased By -402.5 (-3.27%)
BR30 37,383 Decreased By -1494.9 (-3.85%)
KSE100 111,070 Decreased By -3790.4 (-3.3%)
KSE30 34,909 Decreased By -1287 (-3.56%)

GENEVA: The World Health Organization on Friday approved Johnson & Johnson's Covid-19 vaccine, after already authorising the jabs made by Pfizer-BioNTech and Oxford-AstraZeneca.

"Every new, safe and effective tool against Covid-19 is another step closer to controlling the pandemic," WHO chief Tedros Adhanom Ghebreyesus said in a statement.

The news comes after the single-dose jab won approval from the European Union on Thursday.

It has also received the green light from regulators in the United States, Canada and South Africa.

The World Health Organization said the J&J jab had been granted an "emergency use listing" which assesses the suitability of new health products during public health emergencies, and is quicker than the regular licensing system.

Comments

Comments are closed.